HHeadlines Read More PSMAddition data show Novartis Pluvictoâ„¢ delays progression to end-stage prostate cancerOctober 19, 2025 PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR…